Introduction
============

Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the central nervous system (CNS) caused by reactivation of the JC virus (JCV). PML often occurs in patients who are immunosuppressed or who are receiving immunosuppression therapy ([@B1]). Cryptococcal meningitis is another condition that occurs in immunosuppressed conditions and remains a major cause of human immunodeficiency virus (HIV)-related mortality worldwide ([@B2]). Given the recent increase in the use of immunosuppression therapy for rheumatologic conditions, oncology, and organ transplantation, the incidence of PML and cryptococcal meningitis is increasing ([@B3]-[@B7]).

Two commonly used immunosuppressive drugs are methotrexate (MTX) and infliximab. MTX is an analogue of the B vitamin folic acid that is used as first-line immunosuppression therapy for patients with rheumatoid arthritis ([@B8]). Infliximab is a monoclonal chimeric antibody directed against soluble and membrane-bound tumor necrosis factor alpha (TNFα) that prevents receptor binding and blocks gene transcription ([@B9]). Although these agents are effective for rheumatoid arthritis, they may increase the risk of opportunistic infections.

We herein report a patient diagnosed with concurrent PML and cryptococcal meningitis while receiving infliximab and methotrexate treatment for rheumatoid arthritis.

Case Report
===========

A 65-year-old woman was admitted to our hospital because of transient acute right upper limb weakness and gait disturbance. Her medical history revealed that she had been diagnosed with rheumatoid arthritis at 57 years of age and started on 3 mg/day prednisolone and weekly oral methotrexate (6 mg). At 61 years of age, infliximab had been administered every 8 weeks, and prednisolone was reduced to 2 mg/day. Because of remission, prednisolone had been reduced to 1 mg/day and oral methotrexate to 4 mg. At 64 years of age, prednisolone was discontinued due to remission of symptoms. Until admission, remission of arthritis symptoms had been maintained with oral methotrexate (4 mg) and infliximab (3 mg/kg). She had no history of diabetes mellitus during the treatment period.

On admission, she was 151 cm tall and weighed 52.2 kg. She was alert and well oriented. Her cranial nerve function was intact. Slight weakness of the right upper and lower limbs was noted. Although there was no objective sensory loss, she complained of numbness of the right fingers. Her cognitive function was normal, her Revised Hasegawa\'s Dementia Scale (HDS-R) score was 28 points, and her mini mental state examination score was 30. Brain computed tomography (CT) showed no hemorrhagic changes. Brain magnetic resonance imaging (MRI) showed no abnormal intensity areas on diffusion-weighted imaging (DWI). Nonspecific lesions were seen on fluid-attenuated inversion recovery (FLAIR) images ([Fig. 1A](#g001){ref-type="fig"}). A neurological examination was normal on the second hospital day, and a transient ischemic attack (TIA) was diagnosed. The patient was discharged four days later as there was no recurrence of limb palsy or TIA symptoms.

![Changes in brain magnetic resonance imaging (MRI) over time. Fluid-attenuated inversion recovery (FLAIR) scans at first admission (A) and two months (B), three months (C), and six months (D) after the first admission. (A) shows nonspecific changes. (B) shows focal lesions in the white matter of the bilateral frontal and temporal lobes. (C) shows that the lesions in the white matter on FLAIR grew. (D) shows that the lesions gradually disappeared, and no new lesions developed.](1349-7235-58-2703-g001){#g001}

After discharge, the patient reported onset of headache and general fatigue. Eight weeks later, she was readmitted with headache, nausea, dizziness, weight loss, and double vision. At that time, her weight was 45 kg, her cognitive function was mildly disturbed, and her HDS-R score was 16 points. A neurological examination revealed a drowsy state and bilateral sixth nerve palsy. Other cranial nerve functions and muscle strength of the extremities were normal. There were no meningeal signs, such as neck stiffness or Kernig\'s sign. The finger-to-nose and heel-to-knee tests showed no abnormalities. Deep tendon reflexes were slightly increased in the upper and lower extremities. The patient could not walk without assistance due to headache, dizziness, and double vision.

Blood tests showed a normal white blood cell count (5,400 cells/μL; reference 3,300-8,600 cells/μL) with decreased lymphocytes (4.0%; reference 21.3-50.2%). Blood chemistry demonstrated normal C-reactive protein and β-D-glucan levels, and the HIV antibody test were negative. In addition, blood glucose levels were normal (143 mg/dL; reference 60-160 mg/dL). A cerebrospinal fluid examination (CSF) revealed an elevated white blood cell count (23 cells/μL, monocyte 22 cells/μL, polymorphonuclear count 1 cell/μL; reference 5 or less cells/μL) with an opening pressure of over 30 cmH~2~O. The protein concentration in the CSF was increased (199 mg/dL; reference 10-45 mg/dL). The glucose level in the CSF was 22 mg/dL, and the ratio of the CSF/blood glucose was decreased (0.15; reference \>0.4). Cryptococcal antigen was detected in the CSF and serum. A direct examination with India ink staining of the CSF and CSF culture identified *Cryptococcus neoformans*.

Brain MRI revealed focal lesions in the white matter of the bilateral frontal and temporal lobes ([Fig. 1B](#g001){ref-type="fig"}). These lesions appeared hyperintense on T2-weighted and FLAIR images and hypointense and devoid of contrast enhancement on T1-weighted images.

The clinical course is summarized in [Fig. 2](#g002){ref-type="fig"}. We diagnosed the patient with cryptococcal meningitis based on the results of the CSF examination. MTX and infliximab were discontinued, and treatment with amphotericin B intravenously in combination with flucytosine was started. After six weeks, induction therapy succeeded, and fluconazole was started for maintenance therapy. Three weeks after starting antifungal therapy, polymerase chain reaction (PCR) targeting the JCV large T gene in CSF revealed the presence of JCV-DNA showing 479 copies/mL (reference \<50 copies/mL). The JCV genome in CSF showed a mutation characteristic of the PML-type virus identified in the non-coding control region (NCCR) using multiplex real-time PCR ([@B10]). Based on MRI findings and PCR test results for JCV in CSF, we diagnosed her with probable PML. Antifungal therapy was continued without restarting MTX and infliximab, and no other alternative immunosuppressive agents were started. The patient\'s clinical symptoms gradually improved without recurrence of rheumatoid arthritis. Follow-up MRI performed one month after readmission showed enlargement of some lesions and the appearance of new lesions ([Fig. 1C](#g001){ref-type="fig"}). At that time, DWI showed slight hyperintensity of the lesions and a partial low signal on the apparent diffusion coefficient map.

![Summary of the clinical course. Methotrexate and infliximab were discontinued, and antifungal therapy was initiated at readmission. The patient symptoms improved over 10 weeks, and there was no recurrence \>24 weeks after the first admission.](1349-7235-58-2703-g002){#g002}

Given the lack of focal neurological symptoms, we closely monitored the patient\'s condition without treatment, other than antifungal therapy. Eight weeks after readmission, she was discharged with improvement in double vision. Her cognitive function became normal, and her HDS-R score was 28. Two months after discharge, JCV DNA in CSF was negative, and MRI findings showed slight improvement ([Fig. 1D](#g001){ref-type="fig"}). At the time of writing, the patient had been stable for over six months.

Discussion
==========

The patient in the present case was diagnosed with PML and cryptococcal meningitis. Brain imaging and CSF examinations at the time of secondary admission revealed *Cryptococcus neoformans* infection and JCV reactivation. Clinical symptoms of headache, nausea, dizziness, bilateral sixth nerve palsy, and cognitive dysfunction were observed. These symptoms are frequently observed in cryptococcal meningitis ([@B6]), and they gradually improve after starting antifungal therapy without the improvement of MRI findings. Therefore, we considered the symptoms of secondary admission to have been caused by cryptococcal meningitis.

PCR of the patient\'s CSF DNA was positive for JCV, which had the mutation within the NCCR of the viral genome. JCV infection is common in humans and JCV DNA (archetype) is usually found in the blood or urine in non-PML patients. However, JCV variants with NCCR mutations (PML-type) were detected in PML patients ([@B10]). Brain MRI revealed focal lesions in the white matter of the bilateral frontal and temporal lobes. PML and cryptococcal meningitis were therefore simultaneously diagnosed. To our knowledge, there have been only three cases of PML concurrent with cryptococcal meningitis (11-13; [Table](#t001){ref-type="table"}). Cases 1 and 2 were diagnosed PML at an autopsy. Prednisone had been used as an immunosuppressive agent in Cases 2 and 3, whereas biologic agents were administered in our case. Antifungal therapy without antiviral drugs was administered as treatment in all cases; however, only our patient survived. Compared with these previous three cases, the patient in the present case had a short disease duration prior to the diagnosis of cryptococcal meningitis and PML as well as an early administration of antifungal therapy with the discontinuation of immunosuppressive therapy. We suspect that these factors contributed to her good prognosis.

###### 

Known Cases of PML Concurrent with Cryptococcal Meningitis.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case           Age (years)/\     Underlying diseases                          Immunosuppressive agents                                               Cryptococcal meningitis identified   PML identified      Treatment/\                                Outcome (interval)
                 Sex                                                                                                                                                                                            Antiviral drugs                            
  -------------- ----------------- -------------------------------------------- ---------------------------------------------------------------------- ------------------------------------ ------------------- ------------------------------------------ --------------------
  1              49/M\             Sarcoidosis                                  None                                                                   CSF                                  Autopsy             Antifungal therapy and corticosteroids/\   Declined and died\
                 (Mathews 1977)                                                                                                                                                                                 none                                       (60 months)

  2              36/F\             SLE, Thymoma, Aplastic anemia                Prednisone, Oxymetholone, Azathioprine, and Radiotherapy for thymoma   CSF                                  Autopsy             Antifungal therapy/\                       Died\
                 (Malas 1977)                                                                                                                                                                                   none                                       (5 months)

  3              61/M\             Poorly differentiated lymphocytic lymphoma   Cyclophosphamide, Vincristine, and Prednisone                          CSF                                  CT, Biopsy          Antifungal therapy/\                       Died\
                 (Weitzman 1978)                                                                                                                                                                                none                                       (7 months)

  Present case   65/F              Rheumatoid arthritis                         Methotrexate and Infliximab                                            CSF                                  MRI, JC virus PCR   Antifungal therapy/\                       Survived, stable\
                                                                                                                                                                                                                none                                       (6 months)
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SLE: systemic lupus erythematosus, CSF: cerebrospinal fluid, PML: progressive multifocal leukoencephalopathy, CT: computed tomography, MRI: magnetic resonance imaging, PCR: polymerase chain reaction

Cases 1, 2, and 3 are from previously published reports (11-13).

In our case, brain MRI over time showed gradual changes ([Fig. 1](#g001){ref-type="fig"}). In HIV-positive patients with cryptococcal meningitis, MRI findings show leptomeningeal enhancement with or without a micronodular pattern, microcystic prominence involving the temporal lobes or basal ganglia, ventriculomegaly, and brain abscess ([@B14]). In non-HIV patients with cryptococcal meningitis, Virchow-Robin dilatation, hydrocephalus, intracerebral nodules, and pseudocysts are typically present ([@B15]). The MRI findings for our patient differed from those in previous cases of cryptococcal meningitis in all therapy periods. Specifically, PML lesions were seen as a single or multiple hyperintense areas in T2-weighted images with variable shapes and size. Typically, bilateral, asymmetric, multifocal white matter plaque-like lesions that are T1 hypointense do not show enhancement. There is no edema or mass effect, either. On DWI, the advancing edge of the demyelination is strongly hyperintense. For drug-associated PML, lesions are typically localized supratentorially and not infratentorially, especially in the frontal and parietal lobes. Although atypical MRI findings are common, MRI may still be useful for detecting lesions at an early stage of PML ([@B16], [@B17]). In the present case, brain MRI at the initial admission did not show obvious PML lesions. However, the second MRI scan revealed multiple lesions on T2-weighted images and FLAIR hyperintense areas compatible with PML. In addition, the lesions of the bilateral frontal and temporal lobes changed throughout the clinical course.

Cryptococcal meningitis is one of the most important opportunistic infections among immunocompromised hosts, and infection in patients treated with infliximab or MTX has been previously reported ([@B18]-[@B21]). PML has been reported in patients receiving biologic agents, such as natalizumab, efalizumab, rituximab, and infliximab ([@B5], [@B7]). Such biologic immunosuppressive agents are known to have a strong association with drug-induced PML ([@B3]). These immunosuppressants are classified into three categories ([@B22]-[@B24]): Class 1 drugs, including natalizumab, are associated with the highest risk of PML. Class 2 drugs, including rituximab and non-biologic drugs, such as MTX, are recognized to be associated with a lower risk of PML than class 1 agents. Infliximab and other TNF-α inhibitors are class 3 drugs. The risk of developing PML with class 3 drugs remains uncertain, with one report suggesting that a relationship between PML and treatment with anti-TNF agents is unlikely ([@B25]). However, several reports have described an association with PML ([@B5], [@B26], [@B27]). In the present case, the blood cell count showed decreased lymphocyte numbers due to immunosuppression therapy with MTX and infliximab. The decreased T lymphocyte numbers impaired cell-mediated immunity, leading to the breakdown of the prevention of JCV reactivation and cryptococcal infection ([@B6], [@B7], [@B27]). Therefore, PML should be considered in patients receiving combination therapy with class 2 and 3 agents. In addition, TNF-α inhibitors are known to induce CNS demyelination ([@B28]). Although the mechanism is not fully understood, MRI findings from patients treated with TNF-α inhibitors show CNS demyelination as white matter changes on T2-weighted and FLAIR images. This characteristic is similar to PML findings, and we should consider the possibility of PML when changes in MRI findings are noted for patients receiving TNF-α inhibitors.

The recommended approach for drug-induced PML is to exclude suspicious drug use and perform plasma exchange ([@B17]). Although several reports have shown some effectiveness of zidovudine, interferon alpha, foscavir, cidofovir, mitazapine, mefloquine, and comptochecin ([@B29]-[@B31]), the most effective treatment for PML has not been determined. Therefore, many targeted therapies against PML are presently under study. In our patient, we diagnosed probable PML concurrent with cryptococcal meningitis. After starting antifungal therapy and stopping infliximab and MTX, the clinical symptoms and CSF cell count gradually improved. Plasma exchange and drug treatment for PML were not performed in our patient due to her clinical improvement. MRI findings from long-term survivors of PML show leukomalacia and subcortical atrophy ([@B32]), whereas the white matter lesions on MRI in our patient gradually disappeared. Our patient received only an antifungal drug and remained stable over the long term with gradual improvement in MRI findings.

Recently, the occurrence of immune reconstitution inflammatory syndrome (IRIS) has been recognized in association with the treatment of cryptococcal meningitis and PML. IRIS is characterized by a tissue-destructive inflammatory response after initiating highly active antiretroviral therapy (HAART) for HIV or tapering or discontinuing immunosuppressive drugs. IRIS should be considered when clinical symptoms develop and atypical imaging findings are noted despite adequate treatment. IRIS can manifest as cryptococcal meningitis or PML, which is known as cryptococcal meningitis-IRIS or PML-IRIS, respectively. The risk factors of IRIS are pre-treatment HIV or a severe immunosuppressive state with very low CD4 counts and increasing CD4 counts after the initiation of therapy ([@B33]). In the present case, IRIS was not observed after the discontinuation of immunosuppressive agents. The patient did not have HIV, and the recovery of her immune function was slow, as the lymphocyte and CD4 cell counts had been decreased for 17 and \>24 weeks, respectively. We suspected the occurrence of IRIS was prevented by these characteristics.

We also evaluated JCV with mutation within the NCCR of the viral genome. Many kinds of rearranged NCCR of JCV variants (PML-type) have been reported, and the frequent NCCR typing changed in accordance with either the vial load or therapeutic intervention. The NCCR of JCV variants can be used to evaluate PML progression, and changes in NCCR typing can be used as a biomarker of PML treatment in the future ([@B34]).

In summary, we encountered a case of simultaneous development of PML and cryptococcal meningitis in a patient receiving MTX and infliximab. All patients treated with immunosuppressive therapy, including monoclonal antibodies, require careful monitoring, and if neurological symptoms are noted, CNS infection should be considered. In particular, multiple infections should be considered in immunosuppressed patients.
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